35 drugs will be negotiated for medical insurance: several imported new drugs, such as sophopewer and oxitinib, are listed

Source: medicine magic cube on December 5, 2017, the Department of human resources and social security of Zhejiang Province issued the announcement on inviting to participate in the negotiation on special drugs for serious illness insurance in Zhejiang Province, which decided to include 35 drugs into the second round of negotiation on special drugs for serious illness insurance in Zhejiang Province, and sincerely invited manufacturers to participate in the negotiation The Department of human resources and social security of Zhejiang Province requires the manufacturer to confirm the registration by phone before 17:00 on December 6, 2017 If the manufacturer fails to register within the specified time, it shall be deemed as giving up the negotiation These 35 varieties include 7 renewal negotiation drugs and 28 new negotiation drugs The specific list is as follows: infliximab and cetuximab, which were out of the national health insurance negotiation before the new drugs were added in the renewal negotiation, still received the invitation of renewal negotiation a from Zhejiang Province In 2017, a large number of imported new drugs with clinical benefits were approved for listing in China through priority review, but they failed to catch up with the 2017 national health insurance catalog adjustment Before the dynamic adjustment plan of the medical insurance catalog was clear, Zhejiang Province took the lead in throwing olive branches to these star drugs, such as tagrisso, sovaldi, imbruvica, jakavi and ofev If we can enter the local medical insurance through provincial negotiation, it will be a good way for new drugs to occupy the market quickly Then